CYTADREN Drug Patent Profile
✉ Email this page to a colleague
When do Cytadren patents expire, and when can generic versions of Cytadren launch?
Cytadren is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in CYTADREN is aminoglutethimide. Additional details are available on the aminoglutethimide profile page.
Summary for CYTADREN
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 111 |
Clinical Trials: | 1 |
Patent Applications: | 634 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CYTADREN at DailyMed |
Recent Clinical Trials for CYTADREN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Janssen Pharmaceuticals | Phase 2 |
H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
National Cancer Institute (NCI) | Phase 2 |
Anatomical Therapeutic Chemical (ATC) Classes for CYTADREN
US Patents and Regulatory Information for CYTADREN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for CYTADREN
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
Novartis | CYTADREN | aminoglutethimide | TABLET;ORAL | 018202-001 | Approved Prior to Jan 1, 1982 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |